The neuroprotective efficacy of the DPP-4 inhibitor linagliptin against stroke is not mediated by GLP-1 receptor activation

被引：0
|
作者：
Darsalia, V. [1 ]
Larsson, M. [1 ]
Nathanson, D. [1 ]
Drucker, D. J. [2 ,3 ]
Nystrom, T. [1 ]
Klein, T. [4 ]
Patrone, C. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Sci & Educ, Sodersjukhuset, Internal Med, Stockholm, Sweden
[2] Univ Toronto, Mt Sinai Hosp, Dept Med, Toronto, ON M5S 1A1, Canada
[3] Univ Toronto, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5S 1A1, Canada
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
71
引用
收藏
页码：S35 / S35
页数：1
相关论文
共 50 条
  • [41] GLP-1 receptor agonist versus DPP-4 inhibitor and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes
    Xu, Yang
    Fu, Edouard L.
    Clase, Catherine M.
    Mazhar, Faizan
    Jardine, Meg J.
    Carrero, Juan J.
    KIDNEY INTERNATIONAL, 2022, 101 (02) : 360 - 368
  • [42] Contributing Factors for Initiation of GLP-1 Agonist, DPP-4 Inhibitor or Insulin after Metformin or Sulfonylurea in US
    Mehin, Nazanin
    Schwartz, Stanley
    Wang, Hongwei
    Chou, Engels
    Fournier, Marie
    Miao, Wenfeng
    Zhang, Quanwu
    DIABETES, 2012, 61 : A619 - A619
  • [43] Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations
    Migoya, E. M.
    Miller, J. L.
    Larson, P. J.
    Tanen, M. R.
    Hilliard, D.
    Deacon, C. F.
    Gutierrez, M. J.
    Stoch, S. A.
    Herman, G. A.
    Stein, P. P.
    Holst, J. J.
    Wagner, J. A.
    DIABETOLOGIA, 2007, 50 : S52 - S52
  • [44] The Place of GLP-1-Based Therapy in Diabetes Management: Differences Between DPP-4 Inhibitors and GLP-1 Receptor Agonists
    Mize, Dara L. Eckerle
    Salehi, Marzieh
    CURRENT DIABETES REPORTS, 2013, 13 (03) : 307 - 318
  • [45] DPP-4 Inhibitor Linagliptin Attenuates Aβ-induced Cytotoxicity through Activation of AMPK in Neuronal Cells
    Kornelius, Edy
    Lin, Chih-Li
    Chang, Hsiu-Han
    Li, Hsin-Hua
    Huang, Wen-Nung
    Yang, Yi-Sun
    Lu, Ying-Li
    Peng, Chiung-Huei
    Huang, Chien-Ning
    CNS NEUROSCIENCE & THERAPEUTICS, 2015, 21 (07) : 549 - 557
  • [46] Contributing factors for initiation of GLP-1 agonist, DPP-4 inhibitor or insulin after metformin or sulfonylurea in US
    Schwartz, S.
    Fournier, M.
    Wang, H.
    DIABETOLOGIA, 2012, 55 : S349 - S349
  • [47] Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations
    Migoya, Elizabeth M.
    Miller, Jutta
    Larson, Patrick
    Tanen, Michael
    Hilliard, Deborah
    Deacon, Carolyn
    Gutierrez, Maria
    Stoch, Aubrey
    Herman, Gary A.
    Stein, Peter P.
    Holst, Jens J.
    Wagner, John A.
    DIABETES, 2007, 56 : A74 - A74
  • [48] Distinct activation of GLP-1 receptor by exendin-4 and GLP-1
    Montrose-Rafizadeh, C
    Yang, H
    Pritchette, LA
    Eng, J
    DIABETES, 1998, 47 : A192 - A192
  • [49] The risk of acute pancreatitis with GLP-1 receptor agonists and DPP-4 inhibitors: a retrospective observational cohort study
    Koro, C. E.
    Sowell, M. O.
    Stender, M.
    Chhabra, P.
    Allen, J. K.
    Krzywy, H. J.
    DIABETOLOGIA, 2013, 56 : S183 - S184
  • [50] The role of GIP and pancreatic GLP-1 in the glucoregulatory effect of DPP-4 inhibition in mice
    Hutch, Chelsea R.
    Roelofs, Karen
    Haller, April
    Sorrell, Joyce
    Leix, Kyle
    D'Alessio, David D.
    Augustin, Robert
    Seeley, Randy J.
    Klein, Thomas
    Sandoval, Darleen A.
    DIABETOLOGIA, 2019, 62 (10) : 1928 - 1937
12345